NAD and Longevity: What Would Count as Convincing Evidence?

Updated October 25, 2026 · Sources linked below

A longevity claim should tell you what is expected to improve and how that was established. More birthdays, fewer disabling illnesses, better physical function, and a changed blood test are different outcomes. Research on NAD biology does not make them interchangeable.

Follow the evidence from mechanism to outcome

A mechanism explains why an intervention might work. A biomarker can show that a biological pathway changed. A controlled clinical trial can test whether people actually benefit. Each step answers a different question.

Mitochondria and metabolic pathways are important areas of aging research, but an explanation of their role is not evidence that an NAD product extends human lifespan. [1] Even results with an oral precursor in a specific disease cannot establish an anti-aging effect in generally healthy people. [2]

Define healthspan in practical terms

For a patient, meaningful outcomes might include maintaining walking ability, independence, or capacity for everyday activities. Established physical activity guidance addresses several of those goals. [3] A longevity program should explain how an experimental intervention compares with such practical measures, rather than treating a favorable laboratory result as the final objective.

Include burdens and harms

Repeated treatment may involve cost, time, and procedural risk. FDA has reported adverse events involving NAD+ injections and warned about ingredients unsuitable for sterile compounding. These concerns belong in the same conversation as proposed benefits. [4]

Before buying a longevity package

• What specific outcome is supported by human evidence?
• Was the actual product and delivery route studied?
• How long did follow-up last, and were harms measured?
• Would the result change my medical care or daily function?

A transparent discussion can acknowledge scientific interest without promising age reversal. For people considering longevity care in Milton, the strongest starting point remains a clear assessment of health risks, function, and goals—not an assumed need for an infusion.

Sources and further reading

1. NIH: mitochondria and health
2. Brakedal et al. NADPARK phase I randomized trial. Cell Metabolism, 2022
3. National Institute on Aging: exercise and physical ability
4. FDA: ingredients suitable for sterile compounding and NAD+ injection adverse-event reports

Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.